Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first ... a debilitating and progressive disease that results in a range of symptoms, including difficulty ...

Eisai and Biogen have moved swiftly ahead with regulatory ... above the $8,500 and $20,600 justified price range arrived at by the Institute for Clinical and Economic Review (ICER) in a draft ...